Dr. Popper sits on AcuraBio’s board and brings over 25 years of experience in drug discovery and development, diagnostics, GMP facilities, RNA-based technologies, and medical devices for multinational public and private companies.
Dr. Popper also has extensive regulatory experience and a long track record of commercialising a broad range of healthcare innovations, most notably at Baylor College of Medicine and Johns Hopkins University.
